Cancer drugs have been under a critical lens for many years now — and for good reason, according to a duo of new papers.
Two thirds of recently approved cancer drugs just don’t work all that well, particularly when compared to their cost, according to a report in the Annals of Oncology. Another notable conclusion: The paper found no improved benefit from personalized medicine drugs, and first-in-class drugs.
About the Author Reprints
